Samuel Levin

As artificial intelligence dramatically accelerates the design of proteins, manufacturing has become a critical bottleneck for medical breakthroughs reaching patients. The infrastructure for producing biologics has remained largely unchanged for over fifty years, and is capital-intensive, slow to scale, and dependent on fragile supply chains. Neion Bio is replacing nearly every component of this infrastructure, from bioreactors to cell culture media, with nature’s most prolific protein factory: the chicken egg. Enabled by breakthroughs in genome engineering and stem cell technology, Neion creates genetically engineered chickens that lay eggs filled with medicines. As a result, they produce life-saving therapeutics at the cost of egg production, eliminate scale-up risk with simple breeding programs, and solve the problem of resiliency by running on grain and water. A small Neion farm can produce the global supply of essential medicines, and can be set up nearly anywhere in the world.